先进或转移EGFR突变阳性非状非小细胞肺癌的第一线治疗:一个网络元分析
1Department of Oncology, Bishan Hospital of Chongqing Medical University, Chongqing, China.
奥西默提尼布是EGFR M+非小细胞肺癌的首选一线治疗方法,提供更高的生存益处,特别是与化疗相结合时. 需要进一步的研究来验证这些发现.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 具有EGFR突变的晚期或转移性非状非小细胞肺癌 (nsq-NSCLC) 需要有效的第一线治疗.
- 现有的元分析缺乏对多种治疗策略的全面比较.
- 需要进行网络元分析,以评估EGFR M+ nsq-NSCLC的各种治疗方式.
研究的目的:
- 进行网络元分析,比较EGFR M+高级/转移性nsq-NSCLC的第一线治疗方法的疗效和安全性.
- 为了使各种治疗策略的直接和间接比较.
- 提供对治疗选择的彻底评估.
主要方法:
- 在PubMed,Embase,Cochrane图书馆和Web of Science数据库中进行系统搜索,直到2024年5月8日.
- 包括30个随机对照试验 (RCT) 与8654名参与者.
- 主要终点:无进展生存 (PFS) 和整体生存 (OS);次要结果:客观反应率 (ORR) 和3级以上不良事件 (≥3AEs).
主要成果:
- 奥西默蒂尼布 + 化疗 (SUCRAs: 93.4%) 和奥西默蒂尼布 (SUCRAs: 84.61%) 显示出优异的PFS.
- 拉泽提尼布 (SUCRAs: 89.72%),盖菲提尼布 (SUCRAs: 72.07%) 和奥西默提尼布 + 化疗 (SUCRAs: 70.74%) 在 OS 中排名第一.
- 阿法替尼表现出最好的ORR (SUCRAs: 92.27%) 并为≥3AEs (SUCRAs: 74.93%) 是一个有利的选择.
结论:
- 奥西默提尼布是未经治疗的EGFR M+高级/转移性NSQ-NSCLC的首选一线治疗方法,平衡生存率和安全性.
- 将奥西默蒂尼布与化疗结合使用,可以提高存活率.
- 由于研究的局限性,建议进一步进行高质量的研究.
更多相关视频
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mitogens and the Cell Cycle
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
